We are live on ! Find out more
SMMT icon

Summit Therapeutics
SMMT

41 hedge funds and large institutions have $54.6M invested in Summit Therapeutics in 2021 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 17 increasing their positions, 8 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

113% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 8

67% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 6

27% more capital invested

Capital invested by funds: $42.9M → $54.6M (+$11.7M)

11% more funds holding

Funds holding: 37 → 41 (+4)

0.12% more ownership

Funds ownership: 11.09% → 11.21% (+0.12%)

Holders
41
Holders Change
+4
Holders Change %
+10.81%
% of All Funds
0.72%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
17
Reduced
8
Closed
6
Calls
$90K
Puts
–
Net Calls
+$90K
Net Calls Change
+$90K

Top Buyers

Rank Fund Capital Flow
1
PCH
Polar Capital Holdings
United Kingdom
+$2.31M
2
Millennium Management
Millennium Management
New York
+$2.13M
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$683K
4
Goldman Sachs
Goldman Sachs
New York
+$334K
5
LCS
Levin Capital Strategies
New York
+$216K

Top Sellers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
-$3.03M
2
Renaissance Technologies
Renaissance Technologies
New York
-$1.19M
3
ECM
ExodusPoint Capital Management
New York
-$596K
4
Morgan Stanley
Morgan Stanley
New York
-$251K
5
BP
BBR Partners
New York
-$235K

SMMT Hedge Fund Activity: Q1 2021 in Review

41 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Summit Therapeutics (SMMT) for Q1 2021, worth a combined $54.6M — up 27% from $42.9M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new SMMT positions and 6 closed out — a net gain of 4 holders — while 17 added to existing stakes and 8 trimmed.

The largest buyer was Polar Capital Holdings, adding an estimated $2.31M. The largest seller was JP Morgan Chase, cutting an estimated $3.03M.

  • 41 institutional investors held Summit Therapeutics (SMMT) as of Q1 2021, up from 37 in Q4 2020.
  • Funds reported $54.6M of Summit Therapeutics stock for Q1 2021, up 27% quarter-over-quarter.
  • 10 funds opened new Summit Therapeutics positions in Q1 2021 and 6 closed out, a net change of +4 holders.
  • The largest Summit Therapeutics buyer in Q1 2021 was Polar Capital Holdings, an estimated $2.31M added.
  • The largest Summit Therapeutics seller in Q1 2021 was JP Morgan Chase, an estimated $3.03M sold.

Based on aggregated 13F filings for Q1 2021.